Trials / Not Yet Recruiting
Not Yet RecruitingNCT05017402
Higher Dose of Alglucosidase Alpha for Pompe Disease
Higher Dose of Alglucosidase Alpha for Pompe Disease: Long-term Follow-up Study
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 36 (estimated)
- Sponsor
- Taipei Veterans General Hospital, Taiwan · Other Government
- Sex
- All
- Age
- 0 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This study is aimed to investigate that whether the higher dose ERT improve safety and clinical outcomes of Pompe disease patients. Also, wish to develop a new therapeutic recommendation and hope that it could improve the long-term outcomes of Pompe diesease patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alglucosidase Alfa | Standard dose: 20-25 mg/kg every other week; Higher dose: \>25 mg/kg every other week. |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2023-12-31
- Completion
- 2026-12-31
- First posted
- 2021-08-23
- Last updated
- 2021-08-23
Source: ClinicalTrials.gov record NCT05017402. Inclusion in this directory is not an endorsement.